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p53 could help identify bladder tumour cases with a risk of progression from superficial to invasive disease. Semiautomatic, liquid-
based cytology (LBC) techniques offer an opportunity to standardise molecular techniques. The aim of our study was to investigate
whether LBC could improve p53 immunolabelling, and to assess whether urinary p53 could have a prognostic value.
Immunoreactivity for p53 was studied in 198 urine samples after treatment with the Cytyc Thinprep
s processor. After antigen
retrieval, cells were labelled with a monoclonal antibody that recognises both wild-type and mutant form of the p53 protein (Clone
DO-7, Dako), 1/1000. Positivity for p53 was assessed in 17.2% of the cases. High-grade (G3) tumours were positive in 74.1% of the
cases. Comparatively, low-grade (G1–2) urothelial carcinomas were positive in 23.5% of the cases. During a median follow-up period
of 26 months, recurrence was observed in 52.9% of the cases with p53 overexpression, and in only 10.9% of negative cases
(Po0.001). The progression rate was 35.3% of p53-positive cases vs 5.5% of p53-negative cases (Po0.001). Progression-free survival
was significantly shorter in patients with p53 accumulation (P¼0.007). In a multivariate analysis stratified on grade and stage, p53 was
an independent predictor of overall survival (P¼0.042). The results show that using Thinprep
s LBC, p53 immunolabelling of voided
urothelial cells allows most high-grade tumours to be detected and may help identify cases with a higher risk of recurrence and
progression.
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About 70% of superficial (TNM stage pTa–1) bladder urothelial
carcinomas will recur in the 5 years following transurethral
resection (TUR), and 10–20% will progress to muscle invasion
(Saad et al, 2001). Patients treated for bladder cancer are therefore
regularly followed up by cystoscopy and urinary cytology, but to
date, no biological marker has gained wide acceptance in
monitoring for tumour recurrence.
The p53 tumour suppressor gene is located on chromosome 17p.
Mutations and loss of heterozygosity (LOH) commonly induce p53
inactivation, which correlates with protein accumulation in the
nuclei of tumour cells. Numerous studies have shown a clear
correlation between p53 gene mutation and the tumour stage and
grade of bladder tumours (Brandau and Bo ¨hle, 2001). Deletions of
17p have been observed in more than 60% of patients with high-
grade urothelial carcinomas, as well as in those who recur with
muscle infiltration (Friedrich et al, 2001).
Since the initial data that reported a close correlation between
p53 and prognosis, different and somewhat contradictory results
have been published on tissue samples (Schmitz-Dra ¨ger et al,
2000).
In cytological samples, p53 overexpression has been shown to
have only 23.5% sensitivity and 75.0% specificity in detecting
bladder tumours (Righi et al, 1997), but in other series, sequence
analysis of voided urine specimens compared with tissue
samples showed 84.2% sensitivity and 96.8% specificity (Prescott
et al, 2001). For some authors, p53 overexpression in the urine
could aid in predicting prognosis and in identifying cases that are
likely to progress from superficial to invasive disease (Wolf et al,
2001).
Liquid-based cytology (LBC) automatons using filtration and
thin-layer deposition of cells have been developed to replace
cytocentrifugation methods, owing to cell recovery capabilities and
better cell morphology. In the urine, the use of the Thinprep
s 2000
(Cytyc Corp., Boxborough, MA, USA) processor results in
increased cellularity and marked reduction of debris, erythrocytes
and crystals (Anagnostopoulou et al, 2000; Wright and Halford
2001; Piaton et al, 2002, 2004). Additionally, complementary
techniques such as immunocytochemistry, DNA, RNA and protein
molecular analysis can be successfully applied to Thinprep
s-
processed samples, thus allowing the impact of biomarkers in
a variety of human malignancies to be studied (Tisserand et al,
2003).
Considering this background, the present study was under-
taken to investigate (1) whether LBC could help study p53
overexpression in voided urothelial cells and (2) whether p53
overexpression in the urine could be linked to increased risk of
recurrence and/or infiltration in bladder tumour cases.
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The study group consisted of 198 urine samples collected from
consecutive patients viewed at consultation in two departments of
Urology in Lyon, France. The study was approved by the regional
ethics committees. Samples were obtained from male and female
patients at least 18 years old, either consulting for symptoms
possibly indicating bladder cancer (mainly gross haematuria) or
being followed up after complete TUR or bacillus Calmette–
Gue ´rin (BCG) immunotherapy for bladder urothelial carcinoma at
least 1 month earlier.
The results of cystoscopy were recorded as positive (papillary
growth or abnormalities in flat mucosa strongly suspicious
for CIS), suspicious (irregular appearance in flat mucosa, not
otherwise specified) or negative. A TUR was performed in every
case of papillary bladder lesion, and mucosal abnormalities
suspicious for CIS were evaluated by biopsies. Histopathological
characterisation and grading used was that of the WHO/ISUP 1998
classification (Epstein et al, 1998) and the staging was performed
according to the UICC TNM classification.
Whether on initial presentation or during the follow-up, voided
or cystoscopically obtained urine specimens were fixed with an
equal volume of Carbowax (20% polyethylene-glycol 1500 in 50%
ethanol). The resulting samples were sent to the laboratory within
12h, together with clinical and cystoscopy data.
Preparation of LBC slides
After thorough homogenisation, the urine was processed accord-
ing to the instructions for nonmucoid fluids provided by
the manufacturer: samples were washed in phosphate-buffered
saline and cells were resuspended in a Cytolyt
s solution contain-
ing methanol, mucolytic and haemolytic agents. After 30min at
room temperature (RT), cells were centrifuged at 600g for 10min
and resuspended in 45ml PreservCyt
s solution before being
treated.
The Thinprep
s 2000 automaton allows thin-layer cell prepara-
tions to be provided owing to a filtration process: after the
TransCyt
s filter has been plunged into the sample, it rotates at a
high speed and facilitates cell and mucus dispersion. A vacuum is
then applied to the filter, which collects cells on a 5mm porosity
membrane. A software program allows a homogeneous deposition
of cells until saturation. The TransCyt
s filter is then inverted and
a positive pressure allows cells to adhere to an electronegative
slide. After insertion of another TransCyt
s filter and of another
slide, the whole procedure may be repeated until the entire sample
has been treated.
In each case studied, the first slide obtained was stained with
a hypochromic Papanicolaou procedure for cytopathologic evalua-
tion. The second slide, when available, was used for p53
immunocytochemistry: cells were air-dried overnight, wrapped in
metal foil and stored at  201C.
Urinary cytology and histopathology
Cytopathologic analysis was performed at low- and high-power
fields. Normal, inflammatory, reactive and degenerative conditions
of the urothelial component, as described by previous studies
(Murphy, 1990; Bastacky et al, 1999) were considered as negative,
as well as urothelial atypias of undetermined significance. Speci-
mens in which neoplastic cells were recognised (grade 3, grade 2
clearly identified in the pathology report, strong suspicion
for papillary low-grade tumours based on architectural and
nuclear abnormalities) were considered as positive for urothelial
carcinoma (Bastacky et al, 1999).
Histopathological results were separated into three groups: one
positive for high-grade urothelial lesions (pTIS and G3 tumours,
whatever their stage) according to the criteria of the WHO/ISUP
1998 classification (Epstein et al, 1998), one consistent with
low-grade papillary tumours (G1–2, pTa–1 tumours) and one
negative.
Immunostaining methods
Before p53 immunolabelling, slides wrapped in metal foil were
allowed to reach RT for 1h. Cells were then fixed in 95% ethanol
for 30min. In cases where low cellularity did not allow slides to
be prepared for p53 immunostaining, Papanicolaou slides
were destained in 70% ethanol overnight (destained slides – see
Table 3), rinsed in 70% ethanol and then fixed in 95% ethanol
for 30min.
Before labelling, slides were submitted to antigen retrieval for
15min in 0.01 M citrate buffer, pH 6.0, at RT.
Cells were covered with a mouse monoclonal antibody to the
p53 antigen (MoAb M 7001, clone DO-7, DAKO, Glostrup,
Denmark) in a 1/1000 dilution for 1h at RT in a dark wet
chamber. This antibody recognises both wild-type and mutant
forms of the p53 protein. Slides were treated in the Ventana
GenII
s processor (Ventana Medical Systems Inc., Tucson, AZ,
USA) using a diaminobenzidine kit, and were slightly counter-
stained with Harris haematoxylin.
Negative controls were prepared by exclusion of the primary
antibody. Known positive controls were included: slides were
mixed with tissue sections of an archival bladder pT2 G3
urothelial carcinoma known for having 50–65% p53 nuclear
reactivity. The tissue specimen also served as a negative control
after exclusion of the primary antibody. The expression of p53 was
studied in the three groups of cases. A urine sample was
considered as positive for p53 when at least 10 nuclei were
stained, provided at least 100 urothelial cells could be counted in
the whole specimen.
For p53 immunohistochemical detection, tissue samples from
the 73 formalin-fixed, paraffin-embedded TUR and biopsy speci-
mens were stained as follows: representative 5mm sections were
deparaffinised and rehydrated. A pretreatment microwave heating
in 10mM citrate buffer, pH 6.0, was performed before incubation
with the primary antibody.
The sections were treated with the D0–7 antibody at 1/50
dilution for 45min at RT. The reaction was revealed with the
streptavidin–biotin complex method using an LSAB 2 Kit (DAKO
S.A., Trappes Cedex, France). Tissue sections were considered as
positive when at least 10% of nuclei were stained, whatever the
intensity (x–xxx).
Analysis of data
Time to recurrence was calculated from D0 (time of biopsies or
TUR) to the date of the first documented recurrence or the last
follow-up. Progression was defined as tumour recurrence at
a higher stage (TNM stage pTa–1 with increased grade, or
progression from pT1 to pT2 or more) and/or transition from
G1–2 to G3, histologically documented metastases or death from
bladder cancer.
Progression-free intervals were defined as the time between TUR
and invasive tumour growth or G3 recurrence or end of the follow-
up period. Fisher’s exact test and w
2 test with Yates correction were
used to measure the correlation between p53 accumulation and
prognostic factors. Kaplan–Meier plots and the log-rank test were
used to analyse the association of p53 with the time to recu-
rrence and with progression. Two-sided P-values below 0.05 were
considered to be statistically significant.
The Cox proportional hazards model was used for multivariate
analysis of prognostic parameters (age, sex, grade, level of invasion
and p53 status).
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The population studied was composed of 64 women and 134
men, 34–98 years old (mean age¼67.3711.7 years). There were
76 new patients consulting for symptoms possibly indicating
bladder cancer and 122 patients followed up after TUR for bladder
urothelial carcinoma.
There were 121 negative cystoscopy findings, 16 suspicious
mucosal aspects leading to bladder biopsies and 61 typical tumour
growths (Table 1). Overall, 61 bladder tumours were histologically
diagnosed (27 G3 and 34 G1–2 urothelial carcinomas).
Urinary cytology was positive, high grade in 24 of 27 G3
urothelial carcinomas (sensitivity for high grade¼88.9%) and
showed tumour cells of various grades in 42 of 61 tumour cases
(global sensitivity¼68.9%), as shown in Table 2.
The mean volume of the urine samples obtained was
50.47757.67ml (range 30–200).
In the group demonstrating high-grade tumour cells in the
urine, biopsies and TUR showed G3 urothelial carcinoma in 24 of
the 32 cases with histopathological control (75.0%). High-grade
tumour cells were evidenced in eight patients with low-grade
urothelial tumours, probably revealing pTIS lesions not viewed at
the cystoscopy level. These cases were also positive with p53 and
four of eight cases (50.0%) recurred within a 24-month period.
p53 immunoreactivity
LBC allowed a Thinprep
s slide to be prepared for Papanicolaou
staining in every case. However, after the first slide was obtained
by the Thinprep
s processor, the remaining material allowed a
slide for p53 immunocytochemistry to be prepared in 158 out of
198 urine samples (79.8%).
The 40 remaining cases were treated as archival material: the
Papanicolaou slides were destained and treated with the p53 MoAb
as described in the Materials and Methods section. The expression
of p53 was positive in two cases (5.0%), negative in 18 cases
(45.0%) and unsatisfactory for evaluation in 20 cases (50.0%) as
shown in Table 3.
Positivity for p53 was assessed in 34 of 198 urinary cytology
cases (17.2%) in the whole series, including archival material in
two cases. Positivity for p53 was assessed in 32 of 158 cases
(20.3%) obtained after complete Thinprep
s processing.
High-grade tumours were positive for p53 in urine in 20 of 27
cases (74.1%). All had positive, high-grade urinary cytology
results.
Comparatively, low-grade (G1–2) urothelial carcinomas were
positive for p53 in urine in eight of 34 cases (23.5%), including six
cases with urinary cytology findings suggesting low-grade
proliferation (Figure 1).
The eight cases with low-grade urothelial tumours but positive,
high-grade cytology findings showed positivity for p53 immuno-
staining.
Immunoreactivity for p53 was also tested on the tissue samples,
in order to allow comparisons with other series: 22 of 27
Table 1 Cystoscopy and histopathology data in 198 patients
Characteristic n (%)
Negative cystoscopy (biopsy not performed) 121 (61.1)
Suspicious aspects in flat mucosa 16 (8.1)
Negative biopsy 10 (62.5)
Positive biopsy 6 (37.5)
pT2 G3 2
pTIS 4
Positive cystoscopy (papillary lesions) 61 (30.8)
Positive TUR 55 (90.2)
pTa G1–2 34 (61.8)
pTa G3 6 (10.9)
pT1 G3 9 (16.4)
X pT2 4 (7.3)
pTa G2+pTIS 2 (3.6)
Negative TUR 2 (3.3)
TUR not performed 4 (6.6)
Total 198 (100.0)
Table 2 Correlation of urinary cytology (UC) with histopathology
Histopathology (%)
UC results G3 G1–2 Negative Not performed
Pos. high grade 24 (88.8) 8 (23.5) — 2 (1.6)
Low grade — 10 (29.4) — 2 (1.6)
Negative 3 (11.1) 16 (47.1) 12 (100.0) 121 (96.8)
Total 27 (100.0) 34 (100.0) 12 (100.0) 125 (100.0)
Table 3 p53 immunostaining according to urinary cytology (UC) results
UC results (%)
p53 status High grade Low grade Negative Total
Positive
Slides for p53 18 (52.9) 6
a (50.0) 8
b (5.3) 32 (16.1)
Destained slides 2 (5.9) — — 2 (1.0)
Negative
Slides for p53 10 (29.4) 4 (33.4) 80 (52.6) 94 (47.5)
Destained slides — — 18 (11.8) 18 (9.1)
Not conclusive
Slides for p53 4 (11.8) 2 (16.6) 26 (17.1) 32 (16.2)
Destained slides — — 20 (13.2) 20 (10.1)
Total 34 (100.0) 12 (100.0) 152 (100.0) 198 (100.0)
aIncluding two cases without histological confirmation.
bIncluding two false-negative
UC cases with G3 bladder tumours.
Figure 1 p53 immunostaining in a group of low-grade urothelial cells
( 400).
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showed positivity for p53. In comparison, the 12 negative tissue
samples analysed were negative for p53 immunostaining.
Prognostic relevance of p53 alterations in the urine
Most patients were evaluated at 12.074.2 and 2475.6 months
after D0 (time of initial evaluation). During a median follow-up
period of 26 months (range 8–42 months), 36 of 198 patients
(18.2%) had histologically proven bladder recurrence (median
recurrence interval¼13.7 months).
Recurrence was observed in 18 of 34 cases (52.9%) with p53
overexpression, and in only 12 of 112 negative cases (10.7%,
Po0.001). Progression was noted in 18 of 146 valid cases (12.3%)
with a median interval of 14.2 months. Of 18 (66.7%) progression
cases, 12 were observed in patients with p53 positive immunola-
belling.
Of 34 (35.3%) bladder tumours initially recorded as low grade
(pTa–1 G1–2), 12 recurred within a 24-month period (Table 4). In
the same period, progression was noted in six patients including
four cases positive for p53: one pT1 G2 and one pT1 G3 bladder
papillary tumours with CIS were evidenced at 12 and 18 months.
Two pT1 G3 bladder tumours were diagnosed at 18 and 23 months.
One case was a G3 upper urinary tract tumour diagnosed at 12
months in a patient with p53 unconclusive for evaluation at D0,
and there was a pT2 G3 bladder tumour diagnosed at 20 months.
In patients with high-grade tumours at D0, recurrence at 24
months was assessed in 14 of 26 cases (53.8%) and progression was
noted in 10 cases (38.5%).
The progression rate was 12 of 34 (35.3%) p53-positive cases vs
six of 112 (5.4%) p53-negative cases (Po0.001). Progression-free
survival was significantly shorter in patients with p53 accumula-
tion in voided urothelial cells (P¼0.007, log-rank test, Figure 2).
In a multivariate analysis, p53 was an independent predictor of
overall survival (P¼0.042) when compared with age (P¼0.898),
sex (P¼0.996) grade (P¼0.097) and level of invasion (P¼0.750).
DISCUSSION
p53 is located on chromosome 17p13. The p53 gene is mutated in
about 50% of human cancers, and nuclear accumulation of p53
protein demonstrated by immunohistochemistry is recognised as
an independent prognostic factor for disease progression in most
studies (Olumi, 2000). Most patients with allelic loss of 17p or p53
mutation have positive p53 immunoreactivity, as well as patients
with LOH of the p16 locus located on 9p21 (Sourvinos et al, 2001).
However, it has been shown that a fraction of patients with p53
overexpression has no genetic alterations, but has functional
defects in the cell cycle regulation (Friedrich et al, 2001).
In bladder tumours, a number of studies have shown a positive
correlation between p53 overexpression and mutation detection
by DNA sequencing (Stadler et al, 2001; Hopman et al, 2002).
However, p53 nuclear accumulation in the absence of gene
mutation has also been noted.
The first studies of p53 alterations in the urine used a cloning
approach followed by sequencing to confirm the presence of
mutations (Sidransky et al, 1991). Thereafter, several reports have
compared mutations in tissue samples with those found in the
urine: p53 gene mutation in the urine has been shown to correlate
with tumour recurrence or residual (Sachs et al, 2000). Voided
urine specimens and bladder wash specimens have 490%
accuracy in detecting p53 mutations compared with tumour tissue
and show the same mutations after sequencing (Prescott et al,
2001).
Some authors have shown that a number of microsatellite
alterations on p16, p53 and RB1 regions found in cytological urine
specimens were not detectable in the corresponding tumour
biopsies (Sourvinos et al, 2001). Such discrepancies suggest
exfoliation of aggressive cell clones not sampled by biopsies,
that is, originating from CIS areas better detected in cytological
analysis.
However, only a few studies have been devoted to voided urine
specimens, probably because attempts to use p53 as a diagnostic
marker in urine have shown relatively low values (Righi et al,
1997). In the Righi series, the 23.5% sensitivity and 75% specificity
reported render p53 less attractive than conventional urinary
cytology for diagnosing bladder cancer.
Table 4 Progression according to initial histopathological data and p53
results in urine
Status at D0 No. (%)
Recurrence
at 24
months
Progression (%)
12
months
24
months
G1–2 bladder
tumours
34 (17.2) 12 (35.3) — —
p53 positive 8 (23.5) 6 (75.0) 0 4 (50.0)
p53 negative 8 (23.5) 2 (25.0) 0 0
p53 uc 18 (53.0) 4 (22.2) 2 (11.1) 0
G3 bladder
tumours
27 (13.6) 14 (51.9) — —
p53 positive 20 (76.9) 10 (50.0) 4 (20.0) 4 (20.0)
p53 negative 6 (23.1) 4 (66.7) 0 2 (33.3)
p53 uc 0 — — —
Negative
histology
12 (6.1) 0 — —
p53 positive 0 0 — —
p53 negative 12 (100.0) 0 0 (1 nr) 0 (1 nr)
p53 uc 0 0 — —
No histology 125 (63.1) 10 (8.0) — —
p53 positive 6 (4.8) 2 (33.3) 0 (1 nr) 2 (33.3)
p53 negative 84 (66.7) 6 (7.1) 4 (17 nr) 0 (25 nr)
p53 uc 34 (26.9) 2 (5.9) 0 2 (5.8)
Cumulated data 198 (100.0) 36 (18.2) — —
p53 positive 34 (17.2) 18 (52.9) — 12 (35.3)
p53 negative 112 (56.6) 12 (10.7) — 6 (5.4)
p53 uc 52 (26.2) 6 (11.5) — 6 (11.5)
uc¼unconclusive for evaluation; nr¼patient not reviewed.
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Figure 2 Kaplan–Meier progression-free survival curves in patients with
p53-negative and p53-positive urine samples (P¼0.007).
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have been recognised as having a prognostic impact in bladder
urine specimens: a Ki-67 index over 20% may predict those pTa–1
G1–2 tumours that are likely to recur within 1 year of treatment
(Gontero et al, 2000). Patients followed after TUR recur in 50%
of cases when they have a positive uCytþ assay despite negative
cystoscopy in the year following urinary tests (Piaton et al, 2003).
In the literature, data on the prognostic value of p53 are
controversial. The relevance of p53 in muscle-invasive, pT1 G3
bladder tumours is well documented, but the prognostic impact
of p53 alterations in superficial, low-grade tumours remains
uncertain (Friedrich et al, 2001; Wolf et al, 2001). Although some
groups have shown that p53 is a significant predictor of bladder
tumour progression (Schmitz-Dra ¨ger et al, 2000), others have
concluded that it provides no prognostic information (Gontero
et al, 2000; Friedrich et al, 2001).
There are a number of possible explanations for these contra-
dictory results: first, some studies are based on small numbers of
patients with various treatment modalities. Second, differences
between laboratories may be related to the choice of p53 antibody,
labelling protocol and scoring criteria. As stressed by Schmitz-
Dra ¨ger et al (2000), standardisation of p53 immunolabelling is a
matter of primary interest.
There is evidence that interactions between the antibody and
the tissue might influence the outcome of the assay: p53 can be
modified by phosphorylation (or acetylation/ubiquitination) at
several sites, and the consequences of such phosphorylation for
p53 function and epitope masking are still very poorly understood.
DO-7, like DO-1, is sensitive to serine 20 phosphorylation, and this
might underestimate the sensitivity of the assay (Dumaz et al,
2001). However, this aspect is never really discussed in review
articles on p53 immunochemistry.
Although some studies have addressed the detection of mutated
p53 in urine, none to our knowledge has studied the impact of LBC
processing on p53 immunoreactivity. In the present series, LBC
allowed a slide for p53 immunocytochemistry to be prepared in
79.8% of cases, and positivity for p53 was assessed in 32 of 34 cases
(94.1%) after treatment by the Thinprep
s processor.
In our opinion, the good results obtained are due to LBC
technical improvements that allow pre-immunolabelling pro-
cedures to be standardised. In solid tumours such as in breast
carcinomas, other authors have demonstrated that Thinprep
s-
processed samples allowed efficient DNA, RNA and protein
recovery (Tisserand et al, 2003). In addition to improvements
due to software-assisted filtration, the Thinprep
s method allows
unprocessed samples to be stored into the PreservCyt
s solution,
which maintains DNA, RNA and proteins suitable for molecular
analyses even after several months of storage at 41Co ra t 201C
(Tisserand et al, 2003).
In our series, p53 was positive in the urine in 46.7% of the
tumour cases, and in 76.9% of the high-grade bladder tumours.
Only 5.3% of cytologically negative cases were found p53 positive.
Our results are comparable to those of Prescott et al (2001) in
which 19 of 49 (38.8%) histologically confirmed tumours would
have been detected by p53. However, no p53 mutation was
detected in their negative cases.
More importantly, recurrence was observed in 52.9% of our
cases with p53 overexpression, and progression was noted in
12.3% of the patients, 66.7% of progression cases being observed
in patients with p53-positive immunolabelling. In the low-grade
group, it is important to know whether p53 overexpression is
linked to prognosis. From our results, in spite of the low number
of patients, it is interesting to note that among eight cases with
G1–2 bladder tumour and p53 positive in the urine, six (75.0%)
have recurred and four (50.0%) have progressed within a 24-
month period (Table 4).
Both data illustrate that p53 mutation detection has limited
clinical utility for the detection of bladder tumours, but that voided
urine specimens provide a good material for studying p53 in a
prognostic attempt. Our results, combined with those of Tisserand
et al (2003) obtained on cell lines and on breast cancer cells, show
that Thinprep
s LBC provides a very good material for molecular
analysis, and that it could be considered as a technical standard for
cytology-based molecular studies.
We conclude that owing to its negative impact on survival as
demonstrated in this study, p53 in the urine might do more than
play a simple role in identifying bladder tumour cases that may
progress from superficial to invasive disease.
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